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Abstract 27 
 28 
Chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapy 29 
against several malignancies including glioblastoma, the most common and most 30 
aggressive malignant primary brain tumor in adults. The challenges in solid tumor 31 
immunotherapy comprise heterogenously expressed tumor target antigens and 32 
restricted trafficking of CAR T cells to and impaired long-term persistence at the 33 
tumor site, as well as the unaddressed integration of CAR T cell therapy into 34 
conventional anti-cancer treatments. We addressed these questions using a NKG2D-35 
based chimeric antigen receptor construct (chNKG2D) in fully immunocompetent 36 
orthotopic glioblastoma mouse models. ChNKG2D T cells demonstrated high IFN- 37 
production and cytolytic activity in vitro. Upon systemic administration in vivo, 38 
chNKG2D T cells migrated to the tumor site in the brain, did not induce adverse 39 
events, prolonged survival, and cured a fraction of glioma-bearing mice. Surviving 40 
mice were protected long-term against tumor re-challenge. Mechanistically, this was 41 
not solely the result of a classical immune memory response, but rather involved 42 
local persistence of chNKG2D T cells. A subtherapeutic dose of local radiotherapy in 43 
combination with chNKG2D T cell treatment resulted in synergistic activity in 2 44 
independent syngeneic mouse glioma models by promoting migration of CAR T cells 45 
to the tumor site and increased effector functions. We thus provide preclinical proof-46 
of-concept of NKG2D CAR T cell activity in mouse glioma models and demonstrate 47 
efficacy, long-term persistence, and synergistic activity in combination with 48 
radiotherapy, providing a rationale to translate this immunotherapeutic strategy to 49 
human glioma patients. 50 
 51 
 52 
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Introduction 53 
 54 
Glioblastoma is the most common maligant primary brain tumor in adults (1). It 55 
remains one of the most challenging cancers and has still a poor prognosis despite 56 
multimodal treatment regimens comprising surgery, radiotherapy and chemotherapy 57 
with temozolomide (2,3). Therefore, novel treatment modalities are urgently needed. 58 
Adoptive immunotherapy with genetically engineered T cells that express a chimeric 59 
antigen receptor (CAR) is an emerging treatment strategy that may also hold promise 60 
for neoplasms in the central nervous system (CNS) (4).     61 
The design of chimeric antigen receptors, which consist of an extracellular tumor 62 
antigen-binding domain linked to hinge, transmembrane and intracellular signaling 63 
domains (5,6), allows customized T cell engineering and an efficient anti-tumor 64 
response of bulk T cells in a major histocompatibility complex (MHC)-independent 65 
manner (7). CAR T cell therapy has led to encouraging clinical responses in 66 
hematological malignancies (8,9) and is also studied in solid tumors including 67 
glioblastoma (10). However, in solid tumors there are several challenges that hamper 68 
the efficacy of CAR T cell therapy which need to be addressed, such as the 69 
identification of homogeneously expressed tumor-associated or tumor-specific target 70 
antigens, the migration of CAR T cells to the tumor site, and the immunosuppressive 71 
microenvironment that may impede the function and persistence of CAR T cells (11).  72 
CAR T cell strategies that are currently explored against glioblastoma target single 73 
tumor antigens such as epidermal growth factor receptor variant III (EGFRvIII) (12), 74 
erythropoietin-producing hepatocellular carcinoma A2 (EphA2) (13), human 75 
epidermal growth factor receptor 2 (Her2) (14,15) or interleukin 13 receptor subunit 76 
alpha 2 (IL13Rα2) (16). These targets are non-homogeneously expressed and 77 
susceptible to antigen escape (17).  78 
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We and others have assessed the importance of the natural-killer group 2-member D 79 
(NKG2D) system in glioblastoma (18-22), which has unique features such as the 80 
promiscuous binding properties of the NKG2D receptor to multiple tumor-associated 81 
NKG2D ligands and the inducibility of these ligands on the tumor cell surface by 82 
chemotherapy and radiotherapy (23). NKG2D-based CAR T cells elegantly use the 83 
favorable properties of the NKG2D system. The NKG2D CAR design comprises the 84 
full length NKG2D protein fused to CD3ζ and it associates with DNAX-activation 85 
protein 10 (DAP10) at the cell surface. This NKG2D-CD3-DAP10 complex 86 
functionally acts as a second-generation CAR which provides a T cell activation 87 
signal through CD3 and co-stimulation through DAP10 (24,25). NKG2D CAR T cells 88 
have never been tested against intracranially growing tumors such as gliomas. 89 
Furthermore, the combination of CAR T cell therapy with conventional treatment 90 
regimens has never been examined, but the inducibility of NKG2D ligands by various 91 
stressors provides a strong rationale for this approach. 92 
Here, we investigated NKG2D-based CAR T cells in orthotopic, syngeneic glioma 93 
models and addressed the questions of efficacy, trafficking, persistence and 94 
combination with conventional anticancer therapy in fully immuno-competent hosts. 95 
 96 
  97 
5 
 
Material and Methods 98 
 99 
Cell lines 100 
SMA glioma cell lines were obtained from Dr. D. Bigner (Duke University Medical 101 
Center, Durham, North Carolina, USA) and GL-261 cells were obtained from the 102 
National Cancer Institute (Frederick, Maryland, USA). EL-4 cells were obtained from 103 
from the American Type Culture Collection (ATCC, Manassas, Virginia, USA). All cell 104 
lines were maintained in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, 105 
Basel, Switzerland), containing 2 mM L-glutamine (Gibco Life Technologies, Paisley, 106 
UK), and 10% fetal calf serum (FCS, Biochrom KG, Zug, Switzerland) and regularly 107 
tested negative for mycoplasma by PCR. Cells were authenticated routinely at the 108 
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, 109 
Braunschweig, Germany by short tandem repeat analysis, lastly in 2013. 110 
 111 
CAR design and generation of CAR T cells 112 
The design of the murine NKG2D-based CAR (chNKG2D) and the corresponding 113 
control construct that overexpresses wildtype-NKG2D without the intracellular CD3ζ 114 
domain (wtNKG2D) has been described (25). CAR T cells were generated by 115 
retroviral transduction (25). In short, syngeneic splenocytes from C57BL/6 or VM/Dk 116 
mice were activated with 1 µg/ml concanavalin A (Sigma-Aldrich, Steinheim, 117 
Germany) for 18-20 h and retrovirally transduced with chNKG2D or wtNKG2D. The 118 
cells were maintained in RPMI1640 (Gibco Life Technologies, Paisley, UK) 119 
supplemented with 10% FCS, 10 mmol/l HEPES, 2 mM L-glutamine, 1 mmol/l 120 
pyruvate, 0.1 mmol/l non-essential amino acids (all from Gibco), 50 μmol/l 2-121 
mercaptoethanol (Sigma-Aldrich) and 25 IU/ml recombinant murine IL-2 (PeproTech, 122 
London, UK) for 6-8 days and subsequently used for experiments. 123 
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 125 
Antibodies and flow cytometry 126 
The following monoclonal antibodies were used for flow cytometry: anti-CD4-AF700, 127 
anti-CD8-APC, anti-IFN--BV421, anti-CD45.1-AF488 and anti-CD45.2-APC 128 
(BioLegend, San Diego, California, USA). For blocking of FC receptors, samples 129 
were preincubated with anti-mouse CD16/CD32 (Biolegend). As controls, we used 130 
isotype-matched antibodies from Sigma-Aldrich. Acquisition was performed on a BD 131 
FACSVerse Analyzer (BD, Allschwil, Switzerland) and data were analyzed with 132 
FlowJo (Tree Star, Stanford, California, USA).  133 
 134 
Cytotoxicity assay 135 
Glioma cells as target cells were co-cultured for 4 h with chNKG2D or wtNKG2D T 136 
cells at different effector : target ratios. Glioma cell lysis was assessed by a flow 137 
cytometry-based assay (18). Specific lysis was expressed as percentage of death of 138 
labeled target cells. For blocking experiments, transduced T cells were preincubated 139 
for 2 h at 4 °C with anti-NKG2D or isotype control from eBioscience (San Diego, 140 
California, USA). 141 
 142 
Immunohistochemistry 143 
Staining of brain cryosections from tumor-bearing mice has been described in detail 144 
(26). Anti-CD45.1 and anti-CD45.2 antibodies for immunohistochemistry were 145 
obtained from Novus Biologicals (Littleton, Colorado, USA). The Histofine Simple 146 
Stain Mouse MAX PO was obtained from Nichirei (Tokyo, Japan) and used as 147 
secondary antibody system. 148 
 149 
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 151 
Real-time PCR 152 
RNA isolation and cDNA preparation were performed as described (27). Gene 153 
expression was measured in an QuantStudio™ 6 Flex Real-Time PCR System 154 
(Applied Biosystems, Foster City, California, USA) with SYBR Green from Thermo 155 
Fisher Scientific (Waltham, Massachusetts, USA). The following primers (Microsynth 156 
AG, Balgach Switzerland) were used: chNKG2D (28): forward 5′-157 
GGCGTCGACACCATGAGAGCAAAATTCAGCAGGAG-3′, reverse 5′-158 
GGCGCTCGAGTTACACCGCCCTTTTCATGCAGAT-3′, mouse HPRT1: forward 5′- 159 
TTGCTGACCTGCTGGATTAC-3′, reverse 5′- TTTATGTCCCCCGTTGACTG-3′ 160 
respectively. The conditions were 40 cycles at 95 °C/15 s and 60 °C/1 min. Relative 161 
quantification of gene expression was calculated with the ddCT method (29) for 162 
relative quantification compared to the housekeeping gene HPRT1. 163 
 164 
IFN- ELISPOT assay 165 
Individual spleen samples (N=3) were obtained from NKG2D CAR T cell-treated 166 
long-term survivors 8 months after initial treatment or naive control mice. Untouched 167 
T cells were isolated using Pan T Cell Isolation Kit II (Miltenyi Biotec, Bergisch 168 
Gladbach, Germany) and 2 x 106 T cells were co-cultured with GL-261 cells for 24 h. 169 
The number of IFN- secreting cells was measured using mouse IFN- ELISPOT 170 
Ready-SET-Go from eBioscience and spot forming cells (SFC) were counted using  171 
AID EliSpot Reader classic (AID GmbH, Strassberg, Germany).  172 
 173 
IFN- ELISA 174 
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NKG2D CAR T cell-treated long-term survivors, 12 months after initial treatment, or 175 
naïve control mice were (re-)challenged with intracranial implantation of GL-261 cells. 176 
Three days after tumor implantation, mice were euthanized, splenocytes were 177 
isolated and brain-resident CD4+ or CD8+ T cells were FACS-sorted. Subsequently, 5 178 
x 104 splenocytes from long-term surviving mice or naïve control mice were co-179 
cultured with 2.5 x104 GL-261 or EL-4 cells and 5 x 103 FACS-sorted brain-resident 180 
CD4+ or CD8+ T cells were co-cultured with 2.5 x 103 GL-261 or EL-4 cells. After 72 181 
h, cell-free conditioned media was assessed for IFN- by ELISA from Thermo Fisher 182 
Scientific. 183 
 184 
Animal experiments 185 
All experiments were done in accordance with the Institutional Animal Care and Use 186 
Committee (IACUC) of the cantonal veterinary office (ZH006/15) and according to 187 
guidelines of the Swiss federal law on animal protection. Wild-type C57BL/6 CD45.2 188 
mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and 189 
C57BL/6 CD45.1 mice were obtained from the Jackson Laboratory (Bar Harbor, 190 
Maine, USA). VM/Dk mice were bred in pathogen-free facilities at the University of 191 
Zurich. Mice of 6 to 12 weeks of age were used in all experiments. For intracranial 192 
tumor implantation, GL-261 cells (2 x 104) were stereotactically implanted into the 193 
right striatum at day 0. Mice were observed daily and sacrificed as indicated or when 194 
developing neurological symptoms. Where indicated, mice received 5 x 106 195 
chNKG2D or wtNKG2D T cells intravenously at days 5, 7 and 10 after tumor 196 
implantation. For local administration, up to 2 x 106 transduced T cells were injected 197 
intratumorally at day 5 after tumor implantation. If indicated, local cranial radiotherapy 198 
with a single dose of 4 Gy was applied at day 7 after tumor implantation using a 199 
Gulmay 200 kV X-ray unit at 1 Gy/min. Long-term surviving mice were re-challenged 200 
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5-8 months after the initial tumor inoculation with another tumor implantation in the 201 
contralateral hemisphere without any further treatment. For isolation of tumor-202 
infiltrating immune cells at indicated time points, we perfused mice with ice-cold PBS 203 
to remove all circulating leukocytes from the CNS and isolated the brains. 204 
Subsequently, tumor cells were separated from myelin and red blood cells using a 205 
Percoll gradient suspension (Sigma-Aldrich). Cells were washed with PBS and 206 
stained with Zombie Aqua™ Fixable Viability Kit (Biolegend) and fluoro-conjugated 207 
antibodies specific to cell surface markers for flow cytometry as indicated.  208 
 209 
Magnetic resonance imaging (MRI) 210 
MRI was performed with a 4.7 T imager (Bruker Biospin, Ettlingen, Germany) at day 211 
15 after tumor implantation. Coronal T2-weighted images were acquired using 212 
Paravision 6.0 (Bruker BioSpin). If indicated, mean and SD of the tumor volume in 213 
mm3 from 5 mice/group were calculated using the formula (length x width x depth)/2.  214 
 215 
Fluorescence molecular tomography (FMT) 216 
Transduced T cells were labeled with CellBriteTM NIR790 (Biotium, Fremont, 217 
California, USA) and administered to tumor-bearing mice as indicated. For FMT 218 
imaging at indicated time points after T cell injection, mice were anesthetized by gas 219 
anesthesia, depilated at the tumor region, placed in a FMT4000 system 220 
(PerkinElmer, Waltham, Massachusetts USA) and scanned with the 790 nm laser 221 
channel. Image analysis was performed using TrueQuant 3.1 (PerkinElmer). A region 222 
of interest of equal size was placed above the tumor region and fluorescence 223 
intensity was automatically calculated by the software. 224 
 225 
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Statistical analysis 226 
Data are presented as means and SD. Experiments were repeated at least three 227 
times, if not indicated differently. Statistical analyses were performed in GraphPad 228 
Prism (La Jolla, California, USA) using multiple two-tailed Student’s t-tests and 229 
correction for multiple comparisons using the Holm-Sidak method. Kaplan Meier 230 
survival analysis was performed to assess survival differences among the treatment 231 
groups and p values were calculated with the log-rank test. Significance was 232 
concluded at *p < 0.05 and **p < 0.01. 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
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 252 
 253 
Results 254 
 255 
ChNKG2D-transduced T cells lyse glioma cells in a NKG2D-dependent manner   256 
We generated murine chNKG2D CAR T cells or wtNKG2D overexpressing T cells by 257 
retroviral transduction of splenocytes derived from C57BL/6 or VM/Dk mice. NKG2D 258 
cell surface levels in splenocytes transduced with chNKG2D or wtNKG2D were 259 
equivalent (Suppl. Figure 1). The differential biological effects exerted by these cells 260 
can therefore be attributed specifically to the chimeric construct. To determine the 261 
cytolytic activity of chNKG2D- or wtNKG2D-transduced T cells, we used these cells 262 
as effector cells and different syngeneic murine glioma cell lines as target cells in 263 
cytotoxicity assays. ChNKG2D T cells had a significantly higher specific cytolytic 264 
activity against all murine glioma cell lines than wtNKG2D T cells (Figure 1A-D, upper 265 
panels). Inhibition of NKG2D signaling using a blocking antibody abrogated the 266 
enhanced cytolysis, confirming the NKG2D dependency of chNKG2D T cells (Fig. 267 
1A-D, lower panels). Because cytokines are important effector molecules of CAR T 268 
cell function, we assessed the T cell specific IFN- production of chNKG2D or 269 
wtNKG2D T cells co-cultured with syngeneic glioma cells by intracellular cytokine 270 
staining. Both CD4+ and CD8+ T cells produced more IFN- after transduction with 271 
chNKG2D compared to wtNKG2D when the T cells were co-cultured with syngeneic 272 
glioma cells (Figure 2A-D). 273 
 274 
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NKG2D-based CAR T cells home to orthotopic gliomas after systemic 275 
administration 276 
The concept of CNS immune privilege has been refined by the demonstration of an 277 
intact afferent arm of CNS-related immunity which includes the discovery of classical 278 
lymphatic vessels in the meninges (30). However, the efferent arm is restricted, i.e. 279 
leukocyte migration to the brain (31) and the immunosuppressive microenvironment 280 
of solid tumors such as gliomas is another challenge for access of CAR T cells to the 281 
tumor site. To determine whether NKG2D-based CAR T cells reach orthotopically 282 
growing gliomas after systemic administration, we labeled chNKG2D T cells with a 283 
near-infrared dye that allows in vivo tracking by fluorescence molecular tomography 284 
(FMT). After a single intravenous injection of 5 x 106 chNKG2D T cells, we detected a 285 
FMT signal at the orthotopic tumor site that increased over several days (Figure 3A). 286 
Labeled wtNKG2D T cells also reached the tumor site (Suppl. Figure 2). In order to 287 
corroborate this finding, we injected chNKG2D-transduced T cells generated from 288 
splenocytes of CD45.1+ donor mice into CD45.2+ glioma-bearing animals. After tumor 289 
explantation and isolation of tumor-infiltrating immune cells, we detected a CD45.1+ 290 
chNKG2D T cell population by flow cytometry (Figure 3B and Suppl. Figure 3). 291 
Additionally, the infiltration of intracranial tumors with CD45.1+ chNKG2D T cells was 292 
verified by immunohistochemistry (Figure 3C). Compared to direct intratumoral 293 
injection which served as a control, we detected fewer CD45.1+ cells after 294 
intravenous injection, indicating that only a fraction of the administered T cells 295 
migrates to and stays at the tumor site (Figure 3B, C).   296 
 297 
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NKG2D-based CAR T cells prolong survival of syngeneic orthotopic glioma-298 
bearing mice 299 
To explore the efficacy of NKG2D-based CAR T cell therapy against experimental 300 
gliomas in vivo, we intravenously injected chNKG2D or wtNKG2D T cells on days 5, 301 
7 and 10 after orthotopic tumor implantation. This resulted in a significantly prolonged 302 
survival of GL-261 glioma-bearing mice and cured 22% of the animals as confirmed 303 
by MRI and long-term follow-up (Figure 4A). Systemic administration of CAR T cells 304 
may be associated with on-target off-tumor activity and thus local or systemic toxicity. 305 
We did not observe weight loss as an indirect indicator for toxicity following repetitive 306 
systemic administration of chNKG2D or wtNKG2D T cells (Figure 4B). According to 307 
the mouse gene expression database and the BioGPS gene expression database, 308 
NKG2D ligands are generally expressed at low levels in normal tissues with the 309 
highest expression of RAE-1 in liver, hematopoietic system and reproductive system 310 
(Suppl. Figure 4A and B). We observed no changes in liver enzyme amounts in sera 311 
of mice treated repetitively with chNKG2D or wtNKG2D T cells. Furthermore, we did 312 
not observe differences in peripheral blood counts (Figure 4B).  313 
To investigate the potential treatment effect and tolerability in the setting of an 314 
unrestricted migration to the tumor site, we injected chNKG2D T cells directly 315 
intratumorally in glioma-bearing mice. This application route significantly prolonged 316 
the survival after a single injection of chNKG2D T cells in a dose-dependent manner 317 
and increased the fraction of cured mice compared to intravenous CAR T cell 318 
administration (Figure 4C). 319 
 320 
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Glioma-bearing mice surviving after chNKG2D T cell treatment are long-term 321 
protected against tumor re-challenge 322 
An impressive feature of cancer immunotherapy is the potential for a long-lasting 323 
treatment effect (32). We therefore determined a potential long-term immune 324 
protection in glioma-bearing mice that had survived following chNKG2D CAR T cell 325 
treatment. To this end, GL-261 glioma cells were implanted into the contralateral 326 
hemisphere 5-8 months after the first implantation. No additional treatment was 327 
administered. All of these mice that survived after the initial CAR T cell treatment also 328 
survived the tumor re-challenge, and at day 18 after tumor implantation, no tumor 329 
mass was detectable by MRI (Figure 5A and B). In contrast, all naive mice had large 330 
tumors and finally had to be euthanized. In order to investigate the mechanism 331 
underlying this long-term protection, we re-challenged the long-term survivors a 332 
second time and isolated lymphocytes from the brain and from cervical, axillary and 333 
inguinal lymph nodes three days after this second tumor re-challenge. A prominent 334 
CD8+ T cell population was detected within the re-challenged hemisphere of 335 
chNKG2D T cell-treated long-term survivors but not in naive mice (Figure 5C). The 336 
brain-resident CD8+ T cell population predominantly secreted IFN- in response to 337 
GL-261 glioma cells, as demonstrated by FACS-sorting of brain-resident CD4+ and 338 
CD8+ T cells from long-term survivors or naïve tumor-bearing mice three days after 339 
tumor re-challenge and ex vivo stimulation with GL-261 cells or MHC-matched but 340 
non-glioma EL-4 cells (Suppl. Figure 5). There was no difference in intermediate and 341 
high CD44-expressing CD4+ and CD8+ T cells between lymph nodes of re-challenged 342 
chNKG2D T cell-treated long-term survivors and those of naive tumor-bearing mice 343 
(Figure 5D). This suggests a local long-term protection independent from a peripheral 344 
memory response. In line with these findings, we noticed an equivalent tumor cell 345 
cytolysis and IFN- production after co-culture of GL-261 cells with T cells isolated 346 
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from lymph nodes of re-challenged chNKG2D T cell-treated long-term survivors or T 347 
cells from naive tumor-bearing mice.  We detected chNKG2D transcripts in brains 348 
from long-term survivors but not from naive mice and not in peripheral lymph nodes 349 
or spleens from long-term survivors or naïve mice (Figure 5D), which suggests local 350 
persistence of NKG2D CAR T cells in the CNS. 351 
 352 
Irradiation increases the therapeutic activity of NKG2D-based CAR T cells 353 
against gliomas 354 
There is an intense discussion on the implementation of immunotherapy into 355 
conventional treatment regimens. Radiotherapy is part of the standard treatment of 356 
gliomas (33). We have previously observed an upregulation of NKG2D ligands on the 357 
glioma cell surface upon irradiation (23). This built the rationale to combine 358 
radiotherapy with NKG2D-based CAR T cell therapy. A single cranial irradiation with 359 
4 Gy at day 7 after tumor implantation had no effect on survival when given alone but 360 
further increased the activity of NKG2D-based CAR T cells against orthotopic 361 
gliomas as demonstrated by synergistically prolonged survival in 2 independent 362 
glioma models, reduced tumor volume measured by MRI, and an increased fraction 363 
of long-term surviving mice in the SMA-560 glioma model (Figure 6A-D). We 364 
identified two underlying mechanisms for this synergistic activity. Low-dose pre-365 
irradiation of glioma cells and subsequent co-culture with chNKG2D- or wtNKG2D- 366 
expressing T cells resulted in an increased cytolysis and IFN-production in vitro 367 
(Figure 7A). Also in vivo, local tumor irradiation increased the IFN- expression of 368 
tumor-infiltrating chNKG2D T cells (Figure 7B, Suppl. Figure 6A). This points towards 369 
a direct tumor-cell related effect of irradiation that boosts NKG2D CAR T cell activity, 370 
which can be attributed due to the induction of NKG2DL (Suppl. Figure 6B) (23). 371 
Moreover, we observed an indirect migration-related mechanism by tracking 372 
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fluorescently labeled chNKG2D CAR T cells after intravenous injection. Here, we 373 
noticed an increased accumulation of CAR T cells upon irradiation (Figure 7C) 374 
suggesting that local subtherapeutic irradiation promotes the migration of CAR T cells 375 
to the tumor site.   376 
  377 
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Discussion 378 
 379 
CAR T cell therapy is an emerging immunotherapy that is under development against 380 
several malignancies including glioblastoma. However, the potentially 381 
immunosuppressive microenvironment and intraparenchymal location of solid tumors 382 
represent challenges which require a systematic development of strategies boosting 383 
the anti-tumor efficacy of CAR T cells against these tumors (34). Furthermore, it 384 
remains to be determined how immunotherapy with CAR T cells can be integrated at 385 
its best into conventional cancer therapies.  386 
We addressed these questions in orthotopic, fully-immunocompetent, preclinical 387 
glioblastoma models. Except for one report (35), all preclinical studies published so 388 
far have assessed CAR T cells against experimental gliomas in a xenograft setting. 389 
However, only a syngeneic setting which involves an intact immune system and a 390 
physiological tumor microenvironment allows appropriately assessing the challenges 391 
of CAR T cell therapy against solid tumors including potential off-tumor toxicities.  392 
In contrast to other single target antigens for CAR T cell therapy that are currently 393 
being investigated against glioblastoma, the NKG2D CAR elegantly targets multiple 394 
tumor-associated ligands. This may decrease the probability of tumor immune 395 
escape from CAR T cell treatment due to antigen loss (17).  396 
We demonstrate strong anti-tumor activity of NKG2D-based CAR T cells against 397 
glioma cells in vitro in a syngeneic setting (Figures 1, 2). Furthermore, in vivo tracking 398 
of CAR T cells verifies homing of CAR T cells to the intracerebral tumor site after 399 
systemic CAR T cell administration (Figure 3). The target antigens of the NKG2D 400 
CAR are not exclusively expressed on tumor cells but can be induced also in non-401 
tumoral tissues by unphysiological cell stress or inflammation (36-38). Although 402 
NKG2D ligand expression by other tissues may result in on-target off-tumor toxicity, 403 
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we did not observe any signs of toxicity upon systemic CAR T cell administration 404 
(Figure 4B) at the level of body weight, liver function tests or peripheral blood counts. 405 
In line with these findings, a first-in-human phase I trial assessing NKG2D-based 406 
CAR T cells against hematological malignancies has completed enrollment of a first 407 
cohort of patients without treatment-related safety issues (39).  408 
Treatment of glioma-bearing mice with NKG2D CAR T cells resulted in a significant 409 
proportion of surviving mice which were long-term protected against tumor re-410 
challenge in the contralateral hemisphere (Figures 5A, B). In contrast to previous 411 
studies (28,35), this may not only be the result of a classical memory T cell response, 412 
but probably it may also involve long-term persistence of NKG2D CAR T cells in the 413 
brain as demonstrated by detection of the chNKG2D transcripts in the brain tissue of 414 
long-term surviving mice 8 months after initial CAR T cell treatment (Figure 5D). It 415 
remains an open question why NKG2D CAR T cells seem to persist in the CNS but 416 
not in extracerebral organs. Possibly, the CNS as an immune-privileged site provides 417 
a niche for homeostatic proliferation of tissue-resident T cells which allows CAR T 418 
cell persistence. 419 
Future glioblastoma treatment regimens may rely on combination therapies and may 420 
implement novel immunotherapeutic strategies such as CAR T cell administration. 421 
The combination of immunotherapy with conventional anti-cancer treatments such as 422 
radiotherapy may result in synergistic activity (40,41). However, the combination of 423 
CAR T cell therapy with radiotherapy has only been investigated with total body 424 
irradiation used as a myeloablative host-conditioning regimen before administration 425 
of CAR T cells (35). Our data demonstrate synergistic anti-tumor activity of local 426 
tumor irradiation and NKG2D CAR T cell therapy (Figure 6). Mechanistically, this 427 
combination produces stronger CAR T cell activity upon recognition of irradiated 428 
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tumor cells and an improved trafficking of intravenously injected CAR T cells to the 429 
tumor site (Figure 7). 430 
In summary, this study highlights the potential of NKG2D CAR T cells as a promising 431 
therapeutic approach against glioblastoma. Long-term tumor control due to 432 
persistence of these cells at the tumor site and synergistic activity in combination with 433 
radiotherapy suggest that NKG2D CAR T cells represent a novel therapeutic option 434 
that warrants clinical evaluation in glioma patients.  435 
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Figure legends 
 
Figure 1. NKG2D CAR T cells lyse glioma cells in a NKG2D-dependent manner. 
The murine glioma cell lines GL-261 (A), SMA-497 (B), SMA-540 (C) or SMA-560 (D) 
were used as target cells in 4 h cytolysis assays. T cells from C57BL/6 mice (for GL-
261) or VM/Dk mice (for SMA-497, SMA-540 and SMA-560) were transduced with 
chNKG2D (CH) or wtNKG2D (WT) and used as effector cells at various effector : 
target (E:T) ratios (corresponding upper graphs for each cell line). Blocking anti-
NKG2D or isotype control antibodies were used to pre-incubate chNKG2D or 
wtNKG2D T cells for 1 h before using them as effector cells at an E:T of 40:1 
(corresponding lower graphs for each cell line). Data are presented as mean ± SD (*p 
< 0.05; **p < 0.01). 
 
Figure 2. NKG2D-based CAR T cells produce high levels of IFN- upon co-
culture with glioma cells. The murine glioma cell lines GL-261 (A), SMA-497 (B), 
SMA-540 (C) or SMA-560 (D) were co-cultured with chNKG2D- or wtNKG2D-
expressing T cells. After 6 h of co-culture, IFN-γ levels were determined in CD4+ and 
CD8+ T cells by flow cytometry. Bar plots show mean and SD from 2 independent 
experiments (*p < 0.05; **p < 0.01). FACS plots show data from one representative 
experiment and numbers indicate percentage of IFN--positive T cells. 
 
Figure 3. NKG2D-based CAR T cells migrate to intracranially growing gliomas 
after systemic administration. A. ChNKG2D T cells were labeled with CellBrite 
NIR790. Subsequently, 106 labeled cells (+ctrl) or unlabeled cells (PBS, - ctrl 
respectively) were injected intracranially in the brain of a non-tumor-bearing mouse 
and the signal from labeled T cells was detected at the tumor site by fluorescence 
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molecular tomography (FMT) (left). Tumor-bearing mice were treated with a single 
i.v. injection of 5 x 106 chNKG2D T cells at day 5 after tumor cell implantation. The 
near-infrared signal was acquired at the tumor site by FMT at the indicated time 
points after injection (right). Color scales indicate signal intensities. B. Five x 106 
CD45.1+ chNKG2D T cells were injected either intravenously or intratumorally at a 
single time point in CD45.2+ tumor-bearing mice at day 5 after tumor implantation. 
Three days later, tumor-infiltrating immune cells were isolated from the tumor-bearing 
hemisphere and CD45.1+ and CD45.2+ cells were detected by flow cytometry. C. The 
animals were treated as in (B) and CD45.1+ cells were detected by 
immunohistochemistry after removal of the brains at day 10. CD45.1+ T cells are 
stained in brown. Spleen sections from CD45.1+ mice were used as positive control.  
One representative image out of 3 different mice per group is shown. 
 
Figure 4. NKG2D-based CAR T cell treatment confers a survival benefit in 
syngeneic orthotopic glioma-bearing mice. A. GL-261 tumor-bearing mice were 
treated intravenously with 5 x 106 chNKG2D- or wtNKG2D-expressing T cells on 
days 5, 7 and 10 after tumor implantation. Survival data are presented as Kaplan-
Meier plots (left). Representative T2w MRI images of mice receiving wtNKG2D- 
(upper panel) or chNKG2D T cells (lower panel) at day 15 after tumor implantation 
are shown (right). The white arrow indicates the tumor. B. Body weight was 
determined every other day (upper left), liver enzymes (upper right) were assessed at 
day 16 and peripheral blood counts were assessed at day 14 of GL-261 tumor-
bearing mice treated intravenously with 5 x 106 chNKG2D or wtNKG2D T cells at 
days 5, 7 and 10 after tumor-implantation. C. GL-261 tumor-bearing mice were 
treated with a single intratumoral injection of 2 x 104, 2 x 105 or 2 x 106 chNKG2D T 
cells or PBS control. Survival data are presented as Kaplan-Meier plots (left). P 
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values were calculated with log-rank test (*p < 0.05; **p < 0.01). Representative T2w 
MRI images of mice receiving wtNKG2D- (upper panel) or 2x106 chNKG2D T cells 
(lower panel) at day 15 after tumor implantation are shown (right). The white arrow 
indicates the tumor.  
 
Figure 5. Glioma-bearing mice surviving after NKG2D CAR T cell treatment are 
long-term protected against tumor re-challenge. Long-term surviving mice cured 
by systemic (i.v.) or intratumoral (i.t.) administration of chNKG2D T cells were re-
challenged 6 months after the initial tumor implantation with GL-261 cells in the 
contralateral hemisphere. As a control, GL-261 cells were inoculated into naive mice. 
A. Kaplan Meier survival curves for the 3 cohorts are indicated. B. T2w MRI scans at 
day 18 after tumor implantation are shown. The white arrow indicates the tumor. The 
upper panel represents images from naive control mice and the lower panel 
represents images from re-challenged chNKG2D T cell long-term survivors following 
tumor implantation. C. Long-term surviving mice received a second tumor re-
challenge (2 months after the first re-challenge) and three days after tumor (re)-
implantation, tumor-infiltrating CD4+ and CD8+ T cells were isolated and analyzed by 
flow cytometry. An individual plot of tumor-infiltrating lymphocytes from one mouse is 
shown on the left and a diagram depicting the mean and SD of 3 mice shown on the 
right (*p < 0.05; **p < 0.01). D. Same setup as in (C) and isolation of cervical, axillary 
and inguinal lymph nodes at day 3 after the second tumor re-challenge. Effector 
(Teff) and memory (Tmem) T cells were separated using flow cytometry and CD44 
expression levels. Populations with intermediate (effector T cells) or high (memory T 
cells) CD44 expression in the CD4+ or CD8+ T cell compartments are indicated (left). 
The isolated lymph node-derived T cells were used as effector cells in a 4 h immune 
cell lysis assay or IFN- ELISPOT with fresh GL-261 cells as target cells (right upper 
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panel). Real-time PCR for chNKG2D was performed after RNA isolation and cDNA 
preparation from brains, spleens and peripheral lymph nodes isolated 3 days after 
tumor-challenge of naive control mice or 3 days after second re-challenge of long-
term surviving mice 8 months after initial NKG2D CAR T cell treatment (right lower 
panel, with n.d. corresponding to non-detectable). 
 
Figure 6. Irradiation and systemic NKG2D-based CAR T cell treatment act 
synergistically against experimental gliomas. GL-261 (A and C) or SMA-560 (B 
and D) tumor-bearing mice were treated intravenously with 5 x 106 chNKG2D (CH) or 
wtNKG2D (WT) T cells on days 5, 7 and 10 after tumor-implantation either alone or 
with a single local irradiation with 4 Gy at day 7 after tumor implantation. A, B. Kaplan 
Meier curves are shown and p values were calculated with log-rank test (**p < 0.01 
for WT vs. CH; ***p < 0.001 for WT+IR vs. CH+IR). C. Representative MRI scans at 
day 15 of 5 3 animals of each of the 4 cohorts of GL-261 tumor-bearing mice are 
shown (left). The white arrow indicates the tumor. Tumor volumes (right) were 
calculated based on MRI analyses using the formula H x W x L/2 (*p < 0.05 and **p < 
0.01 for WT vs. CH or WT+IR vs. CH+ IR, +p < 0.05 for CH vs. CH+IR). D. Same 
setting as in C but for SMA-560 tumor-bearing mice.  
 
Figure 7. Irradiation-mediated boosting of CAR T cell activity relies on direct 
effects on tumor cells as well as increased CAR T cell migration. A. GL-261 
cells, pre-irradiated (+IR) 24 h prior to the assay with 4 Gy or not were used as target 
cells in cytotoxicity assays using chNKG2D (CH) or wtNKG2D (WT) T cells as 
effector cells at the indicated E:T ratios (left). After 4 h of co-culture at a ratio of 40:1, 
IFN- levels were determined by intracellular cytokine staining and flow cytometric 
assessment (right). Mean and SD are shown (*p < 0.05; **p < 0.01 for WT vs. CH 
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and +p < 0.05; ++p < 0.01 for WT/CH vs. WT/CH + IR). B. 5 x 106 CD45.1+ wtNKG2D 
or chNKG2D were i.v. injected on days 5, 7, 10 after implantation of GL-261 tumors 
in CD45.2+ mice. In addition, mice were irradiated (IR) at day 7 with a single local 
dose of 4 Gy or not. At day 12 after tumor implantation, brain-infiltrating immune cells 
were isolated and IFN- expression assessed in CD45.1+ cells by flow cytometry. 
Mean and SD from 3 mice is shown with **p < 0.01 for WT vs. CH and WT + IR vs. 
CH+IR and +p < 0.05; for WT/CH vs. WT/CH + IR. C. ChNKG2D T cells were labeled 
with CellBrite NIR790. Subsequently, 5 x 106 labeled cells were i.v. injected on days 
5, 7 and 10 after tumor implantation. In addition, mice were irradiated (IR) at day 7 
with a single local dose of 4 Gy or not. The near-infrared signal was acquired at the 
tumor-site by FMT at the following time points: T1 = 24 h prior to IR, T2 = 24 h post 
IR, T3 = 144 h post IR. Representative images are shown on the left and a 
quantification of the detected signal on the right (*p < 0.05; **p < 0.01) 
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Supplementary Figure legends 
Suppl. Fig. 1. NKG2D cell surface expression on transduced T cells. T cells from 
C57BL/6 (left) or VM/Dk (right) mice were transduced to express chNKG2D or 
wtNKG2D and the cell surface expression of NKG2D was assessed for CD4+ and 
CD8+ T cells by flow cytometry. Mean and SD of mean fluorescence intensity (MFI) 
are shown from 2 independent experiments. 
 
Suppl. Fig. 2. wtNKG2D T cells migrate to intracranially growing gliomas after 
systemic administration. wtNKG2D T cells were labeled with CellBrite NIR790. GL-
261 tumor-bearing mice were treated with a single i.v. injection of 5 x 106 wtNKG2D T 
cells at day 5 after tumor cell implantation. The near-infrared signal was acquired at 
the tumor site by FMT at the indicated time points after injection. The color scale 
indicates the signal intensities. 
 
Suppl. Fig. 3. Gating strategy of tumor-infiltrating lymphocytes. Five x 106 
CD45.1+ chNKG2D T cells were injected intratumorally at a single time point in 
CD45.2+ tumor-bearing mice at day 5 after tumor implantation. Three days later, 
tumor-infiltrating immune cells were isolated from the tumor-bearing hemisphere. 
Detailed gating strategy of tumor-infiltrating lymphocytes comprises detection of 
single living, CD45.1+ or CD45.2+ cells.  
 
 
Suppl. Fig. 4. NKG2DL mRNA expression in normal mouse tissues. A. The 
mouse gene expression database (http://www.informatics.jax.org/expression.shtml) 
was assessed for the expression of the main NKG2DL RAEt1a in normal mouse 
tissues. Blue color indicates clearly detected expression by RT-PCR and Northern 
blot, grey color indicates ambiguous expression. B. The BioGPS database 
(http://biogps.org) (B) was assessed for the expression of the RAEt1a in normal 
mouse tissues. Different organ systems are color coded and displayed on the y-axis, 
expression levels are indicated on the x-axis. 
 
Suppl. Fig. 5. Brain-resident CD8 T cells from long-term surviving mice 
predominantly recognize GL-261 cells. Long-term surviving mice (CH_survivor) or 
naïve control (naïve) mice were (re-)challenged with GL-261 cells. Three days later, 
splenocytes were isolated and brain-infiltrating CD4+ or CD8+ T cells were FACS-
sorted. Five x 103 CD4+ (black) or CD8+ (dark grey) T cells or 5 x 104 splenocytes 
(grey) from long-term surviving or naïve control mice were co-cultured with 2.5 x 103 
(in case of brain-infiltrating T cells) or 2.5 x 104 (in case of splenocytes) GL-261 or 
EL-4 cells (MHC-matched non-glioma cells). After 72 h, IFN- production within cell-
free-media was assessed by ELISA). P value was calculated with 2-way ANOVA (**p 
< 0.01). 
 
 
Supp. Fig. 6. Local irradiation increases the effector function of chNKG2D T 
cells in vivo and induces NKG2DL. A. Gating strategy to detect IFN- expression in 
CD45.1+ chNKG2D or wtNKG2D T cells. T cells were injected intravenously at days 
5, 7 and 10 after implantation of GL-261 tumor cells with or without local irradiation of 
4 Gy at day 7, and brain-infiltrating immune cells were isolated at day 12 after tumor 
implantation. B. GL-261 tumor-bearing mice received local irradiation with 4 Gy at 
day 7 after tumor implantation. At day 12, cells from the tumor-bearing hemisphere 
were isolated and NKG2DL expression was assessed by flow cytometry. MFI and SD 
from 3 mice per group is shown (**p < 0.01). 
